S
DNLI icon

SignatureFD’s Denali Therapeutics DNLI Stock Holding History

SignatureFD’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.92K Sell
230
-11
-5% -$226 ﹤0.01% 2811
2026
Q1 		$4.63K Buy
241
+11
+5% +$219 ﹤0.01% 2805
2025
Q4 		$3.8K Hold
230
– – ﹤0.01% 2788
2025
Q3 		$3.34K Sell
230
-99
-30% -$1.42K ﹤0.01% 2796
2025
Q2 		$4.6K Sell
329
-196
-37% -$2.76K ﹤0.01% 2635
2025
Q1 		$7.14K Sell
525
-78
-13% -$1.49K ﹤0.01% 2478
2024
Q4 		$12.3K Buy
603
+39
+7% +$998 ﹤0.01% 2297
2024
Q3 		$16.4K Buy
564
+30
+6% +$744 ﹤0.01% 2132
2024
Q2 		$12.4K Sell
534
-196
-27% -$3.76K ﹤0.01% 2181
2024
Q1 		$15K Sell
730
-190
-21% -$3.57K ﹤0.01% 2136
2023
Q4 		$19.7K Buy
920
+294
+47% +$5.82K ﹤0.01% 1933
2023
Q3 		$12.9K Buy
626
+300
+92% +$7.61K ﹤0.01% 2071
2023
Q2 		$9.62K Buy
326
+105
+48% +$2.95K ﹤0.01% 2253
2023
Q1 		$5.09K Buy
221
+126
+133% +$3.47K ﹤0.01% 2498
2022
Q4 		$2.64K Buy
95
+55
+138% +$1.64K ﹤0.01% 2714
2022
Q3 		$1K Buy
40
+35
+700% +$1.14K ﹤0.01% 2944
2022
Q2 		$0 Sell
5
-48
-91% -$1.26K ﹤0.01% 3157
2022
Q1 		$2K Buy
+53
New +$1.82K ﹤0.01% 2789
2021
Q2 		– Sell
-67
Closed -$4K – 2966
2021
Q1 		$4K Buy
67
+57
+570% +$3.82K ﹤0.01% 2222
2020
Q4 		$1K Buy
+10
New +$605 ﹤0.01% 2408

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SignatureFD's DNLI Position: Q2 2026 in Review

SignatureFD reduced its Denali Therapeutics (DNLI) stake by 4.6% in Q2 2026, selling an estimated $226 and leaving 230 shares worth $5.92K. The position accounts for ﹤0.01% of the portfolio, ranked #2811.

SignatureFD first reported a position in DNLI in Q4 2020 and has held it in 20 quarters since. The position peaked at $19.7K in Q4 2023. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • SignatureFD held 230 shares of Denali Therapeutics worth $5.92K as of Q2 2026.
  • SignatureFD sold 11 Denali Therapeutics shares in Q2 2026, an estimated $226.
  • Denali Therapeutics made up ﹤0.01% of SignatureFD's portfolio in Q2 2026, its #2811 holding.
  • SignatureFD first reported a position in Denali Therapeutics in Q4 2020 and has held it in 20 quarters since.
  • SignatureFD's Denali Therapeutics position peaked at $19.7K in Q4 2023.
  • 292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on SignatureFD's 13F filing for Q2 2026, filed 24 Jul 2026.